Motif Bio plc Warrants to Purchase ADRs
MTFBW
MTFBW was delisted on the 16th of December, 2019.
3 hedge funds and large institutions have $1.7M invested in Motif Bio plc Warrants to Purchase ADRs in 2018 Q2 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 3 → 3 (0)
22% less capital invested
Capital invested by funds: $2.19M → $1.7M (-$490K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$830 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Invesco
Atlanta,
Georgia
| $1.34M | – | – | – |
|
|
SGCM
2
Sand Grove Capital Management
London,
United Kingdom
| $359K | – | – | – |
|
|
3
UBS Group
Zurich,
Switzerland
| $3K | +$830 | +257 | +23% |
|
MTFBW Hedge Fund Activity: Q2 2018 in Review
3 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Motif Bio plc Warrants to Purchase ADRs (MTFBW) for Q2 2018, worth a combined $1.7M — down 22% from $2.19M a quarter earlier.
Fund positioning in MTFBW was balanced in Q2 2018: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, adding an estimated $830.
- 3 institutional investors held Motif Bio plc Warrants to Purchase ADRs (MTFBW) as of Q2 2018, unchanged from Q1 2018.
- Funds reported $1.7M of Motif Bio plc Warrants to Purchase ADRs stock for Q2 2018, down 22% quarter-over-quarter.
- 0 funds opened new Motif Bio plc Warrants to Purchase ADRs positions in Q2 2018 and 0 closed out.
- The largest Motif Bio plc Warrants to Purchase ADRs buyer in Q2 2018 was UBS Group, an estimated $830 added.
Based on aggregated 13F filings for Q2 2018.